Financial Statements

34. Net cash provided by (used in) investing activities

In 2007, there was a net cash inflow of €3,186 million (2006: net cash outflow of €14,730 million), consisting principally of the proceeds from the divestitures of the Diagnostics Division, H.C. Starck and Wolff Walsrode. The principal acquisitions were those of the U.S. cotton seed producer Stoneville Pedigreed Seed Company, the Ure-Tech group of Taiwan, and a biologics manufacturing facility from Novartis. Further details of acquisitions and divestitures are given in Notes [6.2/6.3].

Cash outflows for additions to property, plant and equipment and intangible assets in 2007 came to €1,860 million (2006: €1,876 million). Disbursements for property, plant and equipment and intangible assets included those for the acquisition of Zymo Genetics and the expansion of the production site for polymer products in Caojing, near Shanghai, China.

Inflows from sales of property, plant and equipment and other assets amounted to €165 million (2006: €185 million). An initial payment of €395 million on the divestiture of the diagnostics business, which was completed at the start of 2007, was received at the end of 2006.

Cash inflows from noncurrent financial assets amounted to €70 million (2006: €850 million).

back to overview